• A Correction to this article was published on 25 January 2018


Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. APS can present with a variety of clinical phenotypes, including thrombosis in the veins, arteries and microvasculature as well as obstetrical complications. The pathophysiological hallmark is thrombosis, but other factors such as complement activation might be important. Prevention of thrombotic manifestations associated with APS includes lifestyle changes and, in individuals at high risk, low-dose aspirin. Prevention and treatment of thrombotic events are dependent mainly on the use of vitamin K antagonists. Immunosuppression and anticomplement therapy have been used anecdotally but have not been adequately tested. Pregnancy morbidity includes unexplained recurrent early miscarriage, fetal death and late obstetrical manifestation such as pre-eclampsia, premature birth or fetal growth restriction associated with placental insufficiency. Current treatment to prevent obstetrical morbidity is based on low-dose aspirin and/or low-molecular-weight heparin and has improved pregnancy outcomes to achieve successful live birth in >70% of pregnancies. Although hydroxychloroquine and pravastatin might further improve pregnancy outcomes, prospective clinical trials are required to confirm these findings.


Almost 35 years after the original description of antiphospholipid syndrome (APS), our understanding of this disorder is still evolving. Although APS was initially described as an acquired, autoimmune thrombophilia, we know today that mechanisms other than coagulation-mediated thrombosis contribute to some clinical manifestations; for instance, complement activation might mediate placental injury, which can cause fetal loss1. APS is an autoimmune disease associated with the presence of autoantibodies. These autoantibodies include anticardiolipin antibodies, anti-β2-glycoprotein 1 antibodies and lupus anticoagulant. Anticardiolipin antibodies are directed against cardiolipin, which is a phospholipid contained in cell membranes. Anti-β2-glycoprotein 1 antibodies are directed against β2-glycoprotein 1 — a cardiolipin-binding factor. Lastly, lupus anticoagulant is a mixture of various autoantibodies, which are detected by the prolongation of phospholipid-dependent coagulation tests.

The diagnosis of APS is based on the combination of clinical features (for example, thrombosis in the arteries, veins and/or small vessels or obstetrical complications such as recurrent miscarriage and placental insufficiency) and the detection of circulating antiphospholipid antibodies. The classification criteria presented in Box 1 are often used as diagnostic tools2. However, other features such as thrombocytopenia and cardiac valve lesions also occur within the spectrum of APS.

Box 1: The classification criteria for definite APS

The revised classification criteria for antiphospholipid syndrome (APS) are referred to as the Miyakis criteria2. A patient has to fulfil at least one clinical criteria and at least one laboratory criteria.

Clinical criteria

Vascular thrombosis

≥1 clinical episode of arterial, venous or small-vessel thrombosis. Thrombosis must be objectively confirmed. If histopathological confirmation is used, thrombosis must be present without inflammation of the vessel wall.

Pregnancy morbidity

  • ≥1 unexplained death of a morphologically normal fetus ≥10 weeks of gestation

  • ≥1 premature delivery of a morphologically normal fetus <34 weeks gestation because of severe pre-eclampsia or eclampsia (defined according to standard definitions) or recognized features of placental insufficiency

  • ≥3 unexplained consecutive miscarriages at <10 weeks of gestation, with maternal and paternal factors (such as anatomical, hormonal or chromosomal abnormalities) excluded

Laboratory criteria

The presence of antiphospholipid antibodies on ≥2 occasions at least 12 weeks apart and <5 years before clinical manifestations, as demonstrated by ≥1 of the following:

  • Presence of lupus anticoagulant in plasma

  • Medium titre to high titre of anticardiolipin antibodies (>40 GPL* or MPL*, or >99th percentile) of immunoglobulin G (IgG) or IgM isotypes

  • Anti-β2-glycoprotein 1 antibodies of IgG or IgM isotypes present in plasma

*GPL and MPL are arbitrary units; 1 GPL or MPL refers to 1 μg of IgG or IgM antibody, respectively. Exact value depends on the assay.

The management of APS has been subject to controversy in recent years. Anticoagulation therapy is considered the cornerstone of therapy; however, the optimal agents and the intensity of treatment remain a matter of debate3. The final treatment decision is dependent on the clinical manifestations, the antiphospholipid antibody profile and the concurrent cardiovascular risk factors. In fact, despite the dearth of studies focused on the influence of treating hypertension, dyslipidaemia and diabetes mellitus as well as cessation of tobacco smoking in those with APS, such measures are considered by experts to be vital to reduce the risk of future thrombosis3.

As APS is a fairly new and rare disease, good-quality data to guide treatment are scarce; treatment decisions have relied on expert opinion in many cases. This Primer provides an update on the pathogenesis, diagnosis and therapeutic aspects of APS from an academic and practical point of view and offers an outlook on future research topics, with the acknowledgement that many established concepts of today may change in ensuing years.


Antiphospholipid antibodies are not specific to APS but can be detected in different clinical settings, including in healthy individuals, in individuals with a history of thrombosis and/or pregnancy morbidity and in individuals with other autoimmune conditions (including systemic lupus erythematosus (SLE)) (Table 1).

Table 1: Prevalence of antiphospholipid antibodies in different clinical conditions

General population

The overall prevalence of antiphospholipid antibodies and APS in the general population remains to be determined, as no robust epidemiological population-based studies have been performed4. Moreover, despite considerable efforts over the past three decades geared towards the standardization of immunoassays that measure antiphospholipid antibodies, profound interassay and interlaboratory variation are still reported5. Consequently, the availability of solid epidemiological data on the prevalence of antiphospholipid antibody positivity and APS in the general population is limited.

Durcan and Petri estimated that the incidence of APS is 5 new cases per 100,000 individuals per year and that the prevalence is 40–50 cases per 100,000 individuals6. The prevalence of catastrophic APS, a rare, life-threatening form of APS, has been estimated to be <1% of all cases of APS7. Studies have estimated that the prevalence of antiphospholipid antibodies in the general population ranges between 1% and 5%, but the antibody titre in most of these studies was low8. An increased prevalence of antiphospholipid antibodies has been reported with ageing, with the highest values reported in healthy centenarians but without an association with clinical manifestations of APS9.


The presence of antiphospholipid antibodies is a risk factor for thrombosis; consequently, the prevalence of antiphospholipid antibodies is higher in individuals with thrombotic or cardiovascular events than in the general population. The APS ACTION group reported a literature review focused on the prevalence of antiphospholipid antibodies in the general population with pregnancy morbidity, stroke, myocardial infarction and deep vein thrombosis. The authors estimated that 13% of individuals with stroke, 11% of individuals with myocardial infarction and 9.5% of individuals with deep vein thrombosis are positive for antiphospholipid antibodies10. Another study in women <50 years of age who had had a stroke showed that 17% were positive for lupus anticoagulant compared with 0.7% in the control group (OR of 43.1)11. Positivity for lupus anticoagulant combined with oestrogen-containing oral contraceptive use or smoking increased the risk further (to an OR of 201.0 and 87.0, respectively11.

Individuals who have had obstetrical complications associated with APS are also at increased risk of developing thrombosis. A case–control study showed that the 12-year cumulative thrombotic incidence rate was significantly increased in women with APS and recurrent miscarriages (incidence of 19.3%, n = 57) compared with women with recurrent miscarriage of unknown aetiology (incidence of 4.8%, n = 86), women with recurrent miscarriage and thrombophilic genetic defects as the only aetiological factor for recurrent miscarriage (incidence of 0%, n = 42) and women who are antiphospholipid antibody-positive but otherwise healthy (incidence of 0%, n = 30)12. These results are in line with a 10-year observational cohort study of 1,592 women, which showed that women who were positive for antiphospholipid antibodies and who had experienced three consecutive spontaneous miscarriages at <10 weeks of gestation or one fetal death at ≥10 weeks of gestation had annual rates of deep vein thrombosis of 1.46% (range 1.15–1.82%), pulmonary embolism of 0.43% (range 0.26–0.66%), superficial vein thrombosis of 0.44% (range 0.28–0.68%) and cerebrovascular events of 0.32% (range 0.18–0.53%); these numbers were significantly higher than in women with mutations predisposing to thrombosis, such as factor V Leiden (rs6025) mutations and prothrombin 20210A (rs1799963) mutations, or in women who were negative for thrombophilia13. This finding was in contrast to a retrospective case–control study showing that the thrombosis rate in women with previous recurrent miscarriages associated with antiphospholipid antibodies is similar to the rate in those with idiopathic recurrent miscarriage14.

Pregnancy complications

The APS ACTION group showed that 6% of patients with relevant pregnancy morbidity were positive for antiphospholipid antibodies10. Recurrent miscarriage is the most frequent complication and is observed in the majority (54%) of women with obstetrical APS included in the European Registry on Obstetric Antiphospholipid Syndrome15. Fetal death is considered to be the consequence of placental dysfunction and is strongly associated with antiphospholipid antibodies16,17. In an analysis of 512 stillbirths enrolled in the Stillbirth Collaborative Research Network from 2006 to 2008, 11% (95% CI 8.4–14.4) of the women were positive for antiphospholipid antibodies18.

Autoimmune diseases

Antiphospholipid antibodies can be detected in association with other systemic autoimmune diseases, most frequently SLE (Table 1). The prevalence of antiphospholipid antibodies among patients with SLE ranges from 15% to 34% for lupus anticoagulant, from 12% to 44% for anticardiolipin and from 10% to 19% for anti-β2-glycoprotein 1 antibodies6. Of individuals with SLE who are positive for antiphospholipid antibodies, 20–50% develop thrombotic events19.

Some reports have described considerable heterogeneity in the prevalence of immunoglobulin G (IgG) isotype anticardiolipin antibodies in SLE, ranging from 2% in individuals of Afro-Caribbean descent to 51% in individuals of Indian descent; the variation is partly explained by differences in the assays used20,21. When investigating the prevalence of antiphospholipid antibodies in Chinese individuals with SLE, a prevalence of 22.4% was found for lupus anticoagulant, 29% for anticardiolipin antibodies and 7.7% for anti-β2-glycoprotein 1 antibodies; these numbers are lower than in white individuals with SLE22. However, the 10-year thrombosis rate and rate of recurrent thrombosis in Chinese individuals with antiphospholipid antibodies was similar to that reported in a European prospective cohort of 1,000 patients with APS22. Thus, the observation of lower antiphospholipid antibody levels in Chinese individuals might represent differences in the assays used.


Antiphospholipid antibody formation

Infectious agents are the main triggers for the formation of antiphospholipid antibodies, a process that is best understood for anti-β2-glycoprotein 1 antibodies. Molecular mimicry between structures of bacteria or viruses and β2-glycoprotein-1-derived amino acid sequences are thought to contribute to the formation of autoantibodies23. In addition, misfolding of β2-glycoprotein 1 can also induce autoantibody formation24. Binding of β2-glycoprotein 1 to the surface protein H of Streptococcus pyogenes induces a conformational change in β2-glycoprotein 1, thereby exposing a cryptic epitope in domain 1 of β2-glycoprotein 1. Mice injected with the mouse protein H–β2-glycoprotein 1 complex developed antibodies against this epitope25. Healthy individuals seem to have the potential to produce antibodies against β2-glycoprotein 1; however, only with the appropriate genetic background or following secondary triggers do these antibodies become pathogenetic.

Two-hit model

Although antiphospholipid antibodies are persistently present, thrombotic events occur only occasionally, suggesting that the development of antiphospholipid antibodies is a necessary but insufficient step in the development of APS and that other factors play a part. Such ‘second hits’ or ‘triggers’ probably push the haemostatic balance in favour of thrombosis and might include environmental factors (such as infection), inflammatory factors (such as concomitant connective tissue diseases) or other nonimmunological procoagulant factors (such as oestrogen-containing contraceptives, surgery and immobility)26. The patient's genetic constitution, in relation to genes encoding inflammatory mediators, might also be a critical variable in the development of clinical APS manifestations. Familial studies suggest a genetic predisposition to APS, in part accounted for by the human leukocyte antigen (HLA) system, with the most consistent associations being those with HLA-DR4 and HLA-DRw53 (Refs 27,​28,​29). Furthermore, the presence of both lupus anticoagulant and anticardiolipin antibodies seems to be associated with these HLA genotypes30. Other genes outside the HLA system might also predispose to the development of APS, including IRF5 (encoding interferon regulatory factor 5) and STAT4 (encoding signal transducer and activator of transcription 4)30.


A striking observation is that patients with antiphospholipid antibodies can experience thrombotic complications in every blood vessel, although deep vein thrombosis (usually in the legs) and ischaemic stroke account for 90% of all complications31. The risk factors for thrombotic complications associated with arterial thrombosis are different from those for venous thromboembolism (including deep vein thrombosis and pulmonary embolism)32, suggesting that the interference of antiphospholipid antibodies with homeostasis in each blood vessel type is unique. Alternatively, it is also possible that the autoantibodies interfere with metabolic pathways, which are differently involved in venous, arterial and microvascular thrombosis. Several mechanisms to explain the prothrombotic effects of antiphospholipid antibodies have been proposed, although none of these suggestions has been proven33 (Fig. 1).

Figure 1: Pathophysiology of antiphospholipid antibody-associated thrombosis.
Figure 1

Thrombus formation associated with the presence of antiphospholipid antibodies involves a multihit model in which the thrombotic response is much stronger after a second hit (for example, a minor vascular injury) owing to the priming of immune cells, platelets and endothelial cells by anti-β2-glycoprotein 1 antibodies (the first hit). Which cells or activation pathways are involved remains under investigation (inset). Complement is activated, which strongly accelerates the formation of a thrombus. LRP8, low-density lipoprotein receptor-related protein 8; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor-κB; TLR, Toll-like receptor.

Antiphospholipid antibodies and thrombosis. Administration of antiphospholipid antibodies to mice, rats or hamsters does not result in spontaneous thrombotic complications. However, in keeping with a ‘multihit’ hypothesis of thrombosis, the thrombotic response after a priming event, such as a minor vascular injury, is much stronger in the presence of antiphospholipid antibodies than after infusion of a control antibody34,​35,​36. This observation in animal models fits with the finding that antiphospholipid antibodies are risk factors for thrombosis in humans. Indeed, individuals with antiphospholipid antibodies will respond more profoundly to thrombotic challenges than those without antiphospholipid antibodies.

Animal models have clearly shown that antibodies against β2-glycoprotein 1, especially those against domain 1, can induce a strong prothrombotic phenotype37,38. The epitopes to which the antibodies against β2-glycoprotein 1 are directed have been identified and were shown to be completely conserved in mice, making the injection of human anti-β2-glycoprotein 1 antibodies in mice a good model for the human situation39.

A few papers have shown that anti-prothrombin antibodies can also induce a prothrombotic phenotype40,41. These experiments are less convincing than the results obtained with anti-β2-glycoprotein 1 antibodies because we do not know whether the epitope on prothrombin to which these autoantibodies are directed is present in mice.

One publication shows that anticardiolipin antibodies can also increase the thrombotic risk in mice, independently of β2-glycoprotein 1 and prothrombin42. However, to prove that anticardiolipin antibodies bind to anionic phospholipids independently of any cofactor is difficult. Moreover, cofactor-independent antibodies are common in infectious diseases that are not associated with an obvious increase in thrombotic risk43.

Activation of endothelial cells, platelets and immune cells. Binding of anti-β2-glycoprotein 1 antibodies to β2-glycoprotein 1 at the cell surface results in the activation of cultured endothelial cells, platelets, monocytes, neutrophils, fibroblasts and trophoblasts as well as expression and release of cell type-dependent activation markers33. Animal models have confirmed that infusion of anti-β2-glycoprotein 1 antibodies increases the protein expression of tissue factor, which is responsible for the activation of the coagulation cascade, in monocytes and vascular homogenates44.

Two important questions remain unanswered: which cell type is the major target for the antibodies, and how is this cell type activated? Different studies have identified different cells, but the major candidates seem to be platelets, endothelial cells and monocytes. It is possible that all are involved — directly or indirectly — through the shedding of prothrombotic microparticles45. How the cells are activated is a more challenging question. Activation of the cells likely involves binding of the β2-glycoprotein-1–antibody complex to Toll-like receptor 2 (TLR2), TLR4, annexin A2 or low-density lipoprotein receptor-related protein 8 (LRP8; also known as apolipoprotein E receptor 2) and activation of their intracellular signal transduction pathway, resulting in a more prothrombotic cellular phenotype (Fig. 1). Of note, LRP8 associates with β2-glycoprotein 1 at the cell membrane46. Studies with knockout mice have confirmed an important role for LRP8, annexin A2 and TLR4 in inducing a prothrombotic or thrombotic phenotype that is dependent on antiphospholipid antibodies44. Other receptors or a combination of the proposed receptors might be necessary to activate cells, but the exact mechanism is not yet completely understood47.

Complement activation. Antiphospholipid antibodies also interfere with complement activation. Indeed, mice deficient in complement factors C3, C5 and C6 showed a reduced thrombotic response following antiphospholipid antibody administration combined with a vascular challenge compared with control mice48. Clearly, both haemostasis and complement activation play a part in the induction of thrombosis by antiphospholipid antibodies. However, because these enzyme cascades are intrinsically connected, activation of coagulation could be the cause and subsequent activation of complement could be the consequence.

Activated protein C resistance. An interesting aspect of antiphospholipid antibodies is that they induce activated protein C resistance in vitro; the autoantibodies compete with activated protein C for the binding to the catalytic phospholipids, thereby limiting the access of protein C to its substrates49. Activated protein C resistance strongly predisposes to venous thromboembolism50. Whether the activated protein C resistance observed in vitro also occurs in vivo is unknown. Indeed, antiphospholipid antibodies also induce prolongation of clotting in vitro51, an observation not observed in patients as they do not bleed52. Animal models should answer the role of antibody-induced activated protein C resistance in the risk of venous thromboembolism in individuals with APS.

Pregnancy complications

The pathogenesis of recurrent first-trimester pregnancy loss associated with antiphospholipid antibodies is different from the pathogenesis of morbidity occurring in late pregnancy53. First-trimester pregnancy loss has been attributed to a direct inhibitory effect on proliferation54 of trophoblast cells54,55.

The late obstetrical manifestations of APS, including pre-eclampsia, intrauterine growth restriction and stillbirths, are the consequence of placental dysfunction. Potential causes of these outcomes are: failure of extravillous trophoblasts to adequately remodel the spiral arteries, resulting in reduced maternal blood flow to the placenta and hypoxic injury; inadequate delivery of nutrients to the fetus; and high-velocity and high-pressure blood flow that can damage the placenta56. Antiphospholipid antibodies play a part by reducing proliferation and invasion of extravillous trophoblasts and triggering inflammation at the maternal–fetal interface, which together drive impaired placentation (Fig. 2).

Figure 2: Effect of antiphospholipid antibodies on trophoblasts.
Figure 2

Antiphospholipid antibodies recognizing β2-glycoprotein 1 expressed by trophoblasts promote an anti-angiogenic profile and reduce cell proliferation and migration through low-density lipoprotein receptor-related protein 8 (LRP8) (part a), trigger secretion of inflammatory cytokines and chemokines by activating Toll-like receptor (TLR) and inflammasome pathways (part b) and activate complement on the cell surface, leading to neutrophil and monocyte activation with release of reactive oxygen species (ROS), tumour necrosis factor (TNF), antiangiogenic factors (soluble vascular growth factor receptor (sVEGFR)) and tissue factor (TF) (part c). ASC, apoptosis-associated speck-like protein containing a CARD (also known as PYCARD); c5aR, C5a anaphylatoxin chemotactic receptor; miRNA, microRNA; NALP3, NACHT, LRR and PYD domains-containing protein 3 (also known as NLRP3). Adapted with permission from Ref. 219, John Wiley & Sons.

Proliferation and migration of trophoblasts. β2-Glycoprotein 1 is constitutively expressed at the cell surface by all placental trophoblast subpopulations and on maternal decidual endothelial cells57. Anti-β2-glycoprotein 1 antibodies can bind to human trophoblasts and the endothelium through the phospholipid binding site in domain 5 of β2-glycoprotein 1 and in various cell surface receptors. Antiphospholipid antibodies in in vitro studies have been shown to inhibit spontaneous trophoblast migration, increase trophoblast antiangiogenic soluble endoglin secretion and disrupt trophoblast–endothelial interactions in a model of spiral artery transformation58,​59,​60,​61. These effects are mediated by LRP8, which, when activated by β2-glycoprotein 1 crosslinked by anti-β2-glycoprotein 1 antibodies, suppresses migration by reducing IL-6 levels and STAT3 activity59,62. The role of LRP8 in antiphospholipid antibody-mediated fetal loss and intrauterine growth restriction has also been confirmed in vivo62 (Fig. 2a).

Inflammation. Mouse models have been instrumental in defining the role of local inflammation in the pathogenesis of pregnancy complications associated with antiphospholipid antibodies. Administration of polyclonal IgG antibodies from individuals who have APS with high titres of antiphospholipid antibodies or monoclonal human antiphospholipid antibodies to pregnant mice results in fetal resorption and growth restriction63. Antiphospholipid antibodies localize to the placenta, and associated inflammatory responses, particularly complement activation and recruitment and stimulation of neutrophils, are an essential cause of placental insufficiency, fetal loss and growth restriction64. In addition, in vitro studies with human first-trimester extravillous trophoblasts have shown that anti-β2-glycoprotein 1 antibodies trigger production of pro-inflammatory cytokines and chemokines (such as IL-1, IL-7 and IL-8) via TLR4 (Ref. 58) (Fig. 2b).

Complement activation stimulates release of tumour necrosis factor (TNF) and the antiangiogenic factor soluble vascular endothelial growth factor receptor 1 (sVEGFR1; also known as sFLT1) by infiltrating leukocytes, both of which are associated with impaired placentation and the development of pre-eclampsia65,​66,​67 (Fig. 2c). Mice deficient in components of the alternative and classical complement pathways and mice treated with various inhibitors of complement activation are resistant to fetal injury induced by antiphospholipid antibodies64, indicating that both complement pathways contribute to damage. Indeed, the effectiveness of heparin in reducing pregnancy loss in humans may be, in part, because of its capacity to inhibit complement activation. Anticoagulation therapy with hirudin or fondaparinux, which do not affect complement activation, does not prevent pregnancy complications in antiphospholipid antibody-treated mice68. Complement fragment C4d, a marker of classical complement pathway activation, is present in the placentae of women with SLE and/or APS and women with pre-eclampsia, whereas it is absent in healthy controls69,​70,​71. Inherited hypofunctional variants of complement regulators increase the risk of pre-eclampsia in women with SLE who are positive or negative for antiphospholipid antibodies72. Finally, two studies have shown mild hypocomplementaemia in patients with APS, suggesting ongoing activation and consumption of complement components73,74.

Complement C5a–C5aR interactions drive effectors of placental injury, including tissue factor expression in neutrophils and monocytes, oxidative burst75, release of antiangiogenic factors (sVEGFR1)66 and release of TNF (Fig. 2c). That TNF is itself pathogenetic is suggested by studies showing that miscarriage induced by antiphospholipid antibodies is less frequent in mice deficient in TNF or treated with TNF blockers65. Evidence that TNF contributes to the pathogenesis of adverse pregnancy outcomes in humans includes increased TNF levels in the maternal blood and amniotic fluid of individuals with pre-eclampsia76,77 and increased TNF levels at the fetal–maternal interface in intrauterine growth restriction78.

Complement activation also recruits and activates neutrophils (Fig. 2c). Pregnant mice treated with antiphospholipid antibodies show neutrophil infiltration in the placenta, and the deleterious effects of antiphospholipid antibodies on fetal survival and growth are abolished by neutrophil depletion64. Similarly, in antiphospholipid antibody-independent mouse models of pre-eclampsia, neutrophils infiltrate the placenta and their depletion improves placental morphology, recovers spiral artery remodelling and improves pregnancy outcomes67. In both antiphospholipid antibody-dependent and antiphospholipid antibody-independent models, recruitment of neutrophils is triggered by complement activation at the maternal–fetal interface and leads to an increase of local TNF levels, reduction of VEGF levels and, ultimately, abnormal placentation and fetal death.

Neutrophils may also be directly activated by anti-β2-glycoprotein 1 antibodies that recognize β2-glycoprotein bound to their cell surface and stimulate neutrophil extracellular trap (NET) formation through mechanisms dependent on reactive oxygen species and TLR479. Patients with APS show increased NET formation, impaired NET clearance and higher numbers of circulating low-density granulocytes, which have an increased capacity to produce cytokines and type 1 interferons79. Increased numbers of NETs are found infiltrating placental intervillous spaces, in association with inflammatory and vascular changes, in individuals with SLE and with pre-eclampsia80.

Diagnosis, screening and prevention

Antiphospholipid antibody assays

In the current classification criteria for APS (Box 1), testing for lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies is included2. Because clinical manifestations associated with APS are common and often determined by other underlying causes, the laboratory detection of circulating antiphospholipid antibodies defines the disease. The assays for the detection of antiphospholipid antibodies must be sufficiently sensitive and specific to correctly classify patients as having APS because overdiagnosis and misdiagnosis have severe implications for optimal treatment81. Thus, the performance and choice of assays used for detecting antiphospholipid antibodies should be well considered and follow the guidelines82,​83,​84. All assays routinely used to detect antiphospholipid antibodies show methodological shortcomings and lack of standardization52,53,63. Recommendations for the detection of lupus anticoagulant published in 2009 by the Scientific and Standardization Subcommittee on Antiphospholipid Antibodies of the International Society of Thrombosis and Haemostasis (SSC-ISTH) have been useful in the standardization of this assay82. Recommendations for the detection of anticardiolipin and anti-β2-glycoprotein 1 antibodies using immunoassays were published to provide additional details and specifications83 (Table 2).

Table 2: SSC-ISTH guidelines for antiphospholipid antibody detection

Testing for antiphospholipid antibodies should be limited to patients who have a considerable probability of having APS. A generalized search for antiphospholipid antibodies in the absence of any relevant condition is strongly discouraged to prevent incidental findings. Antiphospholipid antibodies should be tested in younger patients (<50 years of age) with unprovoked thrombotic events or thrombosis at unusual sites or in those who have thrombotic or pregnancy complications associated with autoimmune disease82,83. As antiphospholipid antibodies are a heterogeneous group of autoantibodies with overlapping, but not identical, characteristics, it is recommended to perform all assays at the same time with an integrated interpretation of all tests82,83 (Table 2).

Lupus anticoagulant. The lupus anticoagulant assay detects all antiphospholipid antibodies. Detection involves two functional coagulation assays that measure the ability of antiphospholipid antibodies to prolong the phospholipid-dependent clotting time: diluted Russell viper venom time (dRVVT) and the activated partial thromboplastin time (aPTT). An individual is considered positive for lupus anticoagulant if at least one of these tests is positive. Lupus anticoagulant is traditionally detected by a three-step procedure involving a screening, mixing and confirmation step82. A test is defined as lupus anticoagulant-positive if it has an extended coagulation time during the screening step, which is not reversed in the mixing step (where patient plasma is mixed with normal plasma) but is reversed in the confirmation step by the addition of excess phospholipids, which confirms that anticoagulants present in the plasma are specific for phospholipids (that is, antiphospholipid antibodies).

Two tests with distinct performance principles are needed as no coagulation test is 100% sensitive; no other tests but dRVVT and aPTT are recommended to increase the harmonization in lupus anticoagulant testing using robust, reproducible, sensitive, commercially available and quality controlled assays. The mixing step is mandatory to avoid false-positive results. However, some discussion has been raised as coagulation might be corrected if antibody titres are low and because the step is time-consuming and reagent-consuming82,85,​86,​87,​88. One of the major drawbacks of the lupus anticoagulant coagulation assays is their sensitivity to anticoagulant therapy82,89. Elevated factor VIII or C-reactive protein may lead to false-negative or false-positive test results, respectively88. The Taipan snake venom test is useful in those on warfarin treatment as it produces reliable lupus anticoagulant results, although it still labels some lupus anticoagulant-positive samples as negative90.

Anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. Anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies are measured by solid-phase immunoassays; the presence of either IgG or IgM isotypes is considered diagnostic2,83. With lupus anticoagulant tests, all antiphospholipid antibodies are detected independent of the cofactor protein of the antibodies. Immunoassays measure different groups of antiphospholipid antibodies, that is, antibodies towards cardiolipin (anticardiolipin antibody assay) or towards β2-glycoprotein 1 (anti-β2-glycoprotein 1 antibodies assay)91,92, the principal cofactor protein for antiphospholipid antibodies91,92. Methodologically correct anticardiolipin antibody assays with anti-β2-glycoprotein 1 in the reagents have diagnostic value with similar sensitivities and specificities to anti-β2-glycoprotein 1 assays93,94. Detection of the same isotype for both antibodies reinforces the probability of APS82, which is an argument to keep both IgG and IgM isotypes in the classification criteria2,83. A recent review of the literature revealed that thrombosis is more strongly associated with IgG-type antibodies than with the IgM isotype, but the review did not provide an answer on how many cases of APS would be missed if IgM is omitted95. The importance of IgA-type anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies remains controversial; measurement of this isotype is not recommended yet2,83. IgA testing probably has less value in screening but might be useful for confirmation of APS or restricted to patients with a strong suspicion of APS but negative for criteria antiphospholipid antibodies (see below)96,97. The anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies assays show interassay variation owing to differences in calibration and differences in assay characteristics91,98. Coating of the solid phase differs among assays, resulting in different antigen exposure99. Harmonization of working conditions using automated systems may contribute to a reduction in interlaboratory variation100.

Antibody profile. Lupus anticoagulant positivity is regarded as the most important risk factor for APS-related thrombotic events101. However, tests for all three antibodies must be performed to define a patient's full antibody profile, as patients may be positive for only one of the antibodies. The concept of antiphospholipid antibody profiles was recommended initially in the 2006 Sydney APS classification criteria, with a categorization of patients according to their positivity for single or multiple antiphospholipid antibodies, which supports the concept that the antiphospholipid antibody profile defines the risk of developing APS-related events2,102,103. A modification has been proposed that takes into account the type and the number of positive tests26,104. Indeed, evidence has shown that patients with more than one positive test, and particularly those who are triple-positive for lupus anticoagulant, anticardiolipin antibodies (either IgG or IgM) and anti-β2-glycoprotein 1 antibodies (either IgG or IgM), show the strongest association with thrombotic APS105,106. Moreover, triple positivity in individuals with APS is associated with recurrence of thrombosis, whereas triple positivity in asymptomatic individuals is associated with first thrombosis26,107. In individuals with APS, those who are triple-positive usually maintain this profile and show similar results 3 months after the initial test108. However, the guidelines recommend retesting after 3 months to avoid overdiagnosis by classification of transient positivity of antibodies as APS, for example, as in those with a transient increase in antiphospholipid antibodies provoked by infection2,82. In addition, confirming test results ensure the reliability of the positive test, which is important in the context of poor standardization and interferences that affect the test results91,109.

Noncriteria antiphospholipid antibodies. Other antiphospholipid antibodies are not included in a standard test panel owing to the lack of standardization and the absence of evidence on the utility in patients with APS83,97,110,111. The anti-domain 1 β2-glycoprotein 1 antibodies (anti-D1 antibodies), a subgroup of IgG anti-β2-glycoprotein 1 antibodies, were not included in the SSC-ISTH recommendations because adequate clinical studies and a commercial assay were not available at the time of writing83. A strong association of anti-D1 antibodies and thrombosis has been observed using research assays112,113. A commercial chemiluminescence immunoassay assay has now been developed to detect anti-D1 antibodies, and several studies using this assay have confirmed a high odds ratio for thrombosis and the role of anti-D1 antibodies in risk stratification of individuals with APS114,​115,​116,​117,​118,​119. Anti-D1 antibodies (IgG isotype) are mainly detected and present at high titres in triple-positive individuals115,116. However, anti-D1 antibodies are not considered independent risk factors, as illustrated in a limited number of studies115,120. Thus, detection of anti-D1 antibodies is considered a confirmation of the higher thrombotic risk, rather than a candidate for replacement of the anti-β2-glycoprotein 1 antibodies. Addition of antibodies to phosphatidylserine–prothrombin to the current antibody panel shows promising diagnostic value121 but requires further investigation.

Clinical manifestations

The main clinical manifestations of APS are the occurrence of thrombosis (arterial and/or venous) and/or pregnancy morbidity, including recurrent miscarriages, fetal deaths and late pregnancy complications such as pre-eclampsia and intrauterine growth restriction. In addition, APS can be associated with a wide variety of other clinical symptoms (Fig. 3).

Figure 3: Clinical manifestation of antiphospholipid syndrome.
Figure 3

Antiphospholipid antibodies are associated with a variety of symptoms; in particular, deep vein thrombosis, pregnancy morbidity and stroke are frequent (occurring >20% of individuals with antiphospholipid antibodies). Other manifestations vary in frequency, ranging from less frequent (10–20% of individuals with antiphospholipid antibodies), unusual (<10%) and rare (<1%). For example, an unusual manifestation is thrombotic microangiopathy (not shown), which manifests in the skin, kidneys and/or heart. Livedo reticularis most commonly occurs on the upper arms and thighs. Images courtesy of Y. Shoenfeld.

In the past, the terms ‘primary APS’ and ‘secondary APS’ have been used. ‘Secondary’ indicated that APS was associated with another systemic autoimmune disease, usually SLE. However, we have refrained from using these terms, as follow-up of individuals with APS showed that most patients acquired other autoimmune diseases. Furthermore, APS is not ‘secondary’ to SLE in its effect.

Thrombosis. Single or multiple thrombi in veins, arteries and the microvasculature and the time interval between these manifestations may vary from days to years. This variability in location of the thrombi results in the wide spectrum of clinical presentations that may involve many organ systems52,122 (Fig. 3).

Venous thromboembolism, particularly deep vein thrombosis of the lower limbs, is the most frequent manifestation of APS, with a prevalence of 39% in the Euro-Phospholipid Project122. Although arterial thrombosis is less common than venous thromboembolism, it is usually more severe and life-threatening. Indeed, 20% of individuals with APS developed a stroke and 11% developed a transient ischaemic attack. The recurrence rate of thrombotic events in the untreated individuals after unprovoked first events is high and ranges from 19% to 29% per year123. Positivity for lupus anticoagulant, triple positivity and isolated, persistent positivity for anticardiolipin antibodies at medium-high titres are associated with an increased risk of developing thrombosis124.

According to the APS classification criteria, thrombosis must be confirmed by objective validated criteria, such as unequivocal findings of appropriate imaging studies or histopathology. For histopathological confirmation, thrombosis should be present without considerable evidence of inflammation in the vessel wall2.

Obstetrical morbidity. Obstetrical APS can be associated with various pregnancy complications, of which recurrent miscarriage at <10 weeks of gestation is the most frequent15. The maternal pregnancy morbidity of APS consists of pre-eclampsia, eclampsia and placental abruptions. Despite the transplacental transfer of maternal antiphospholipid antibodies, babies born to mothers with APS do not seem to have thrombosis or SLE125. Several risk factors predict poor pregnancy outcome, including an associated systemic autoimmune disease, in particular SLE, a history of previous thrombotic events, reduced complement levels126 and lupus anticoagulant positivity or triple positivity15,127.

Reduced blood flow in the uterine arteries measured by Doppler velocimetry is an indirect indicator for the development of placental insufficiency and/or pre-eclampsia128. Thus, pregnant women with APS should be offered obstetrical ultrasonography to assess fetal growth and amniotic fluid volume and second-trimester Doppler ultrasonography to assess end-diastolic blood flow in the umbilical artery. Normal end-diastolic blood flow in the uterine artery results at 20–24 weeks of gestation is a strong predictor for good fetal outcome129. In a study of 33 women with APS, the positive predictive value of abnormal uterine artery Doppler ultrasonography for later intrauterine growth restriction or pre-eclampsia was 67% with a negative predictive value of 93%130. Another prospective study of 100 pregnancies confirmed that Doppler ultrasonography in the second trimester is the best predictor for late pregnancy outcome in SLE and/or APS129. The European League Against Rheumatism (EULAR) has now included recommendations on the use of uterine artery Doppler ultrasonography in their guideline131.

Neurological manifestations. Stroke is the most common and severe neurological manifestation of APS. However, many other neurological manifestations that are not included in the criteria have been associated with antiphospholipid antibodies, including cognitive dysfunction (owing to several cerebral small vessel thromboses), untreatable headaches and migraine, epilepsy and chorea132. Epilepsy is strongly associated with previous strokes and transient ischaemic attack, SLE, valvulopathy and livedo reticularis (a red or bluish alteration of the skin with a net-like pattern attributed to blood stasis and, occasionally, fibrin deposition in distal venules)133.

Cardiac manifestations. Cardiac features associated with APS vary from valve lesions to accelerated atherosclerosis, myocardial infarction, intracardiac thrombi, pulmonary hypertension, cardiomyopathy and diastolic dysfunction134. Cardiac valve abnormalities are observed in 30–50% of individuals with APS and mainly include valve thickening and regurgitations, but valve vegetations (for example, Libman–Sacks endocarditis) and valve stenosis also occur135,136. The mitral valve is most commonly involved, followed by the aortic valve. Valve damage is most frequent in individuals with APS who also have another autoimmune disease137. Myocardial ischaemic events can result from coronary thrombosis without underlying atherosclerosis, accelerated atherosclerosis of the coronary arteries or microvascular injury. Myocardial infarction is observed in 5.5% of patients in APS registries52,138.

Thrombocytopenia. Thrombocytopenia occurs in at least 30% of individuals with APS and is most marked at times of thrombosis formation52. However, thrombocytopenia might also be associated with other systemic manifestations of APS, such as obstetrical morbidity, venous and/or arterial thrombosis, myocardial infarction and valve vegetations139. The prevalence of thrombocytopenia was found to be higher in individuals with APS who also have SLE than in those with APS alone52,139. However, platelet counts usually remain >50 × 109 per litre; consequently, thrombocytopenia rarely results in major bleeding and does not require intervention. A positive Coombs test (confirming anti-erythrocyte antibodies) occurs in 10% of individuals with APS but is rarely associated with autoimmune haemolysis140.

Pulmonary manifestations. Pulmonary emboli and infarction are the most frequent pulmonary manifestations, affecting 14% of individuals with APS52. Other manifestations are pulmonary hypertension, acute respiratory distress syndrome and intra-alveolar haemorrhage141.

Dermatological manifestations. Dermatological features may be the first clinical presentations of APS. The most frequent is livedo reticularis, which occurs in 16–25% of patients142. Livedo reticularis may be a prognostic marker of more-severe disease associated with the arterial and microangiopathic subtypes of APS143,144. Other manifestations include digital gangrene, skin ulcerations, superficial skin necrosis, pseudovasculitis lesions and pyoderma gangrenosum-like lesions, characterized by deep, necrotic ulcers142.

Renal manifestations. Thrombosis might also result in renal manifestations. A thrombotic microangiopathy associated with antiphospholipid antibodies might manifest with a slow, occult onset of haematuria, proteinuria (ranging from mild to nephrotic) and renal insufficiency, or it may develop acutely and present with acute renal failure and hypertension145. Ideally, the diagnosis of antiphospholipid antibody-associated nephropathy should be supported by a kidney biopsy146, particularly in those with SLE in whom nephropathy may be isolated or concomitant with lupus nephritis.

Catastrophic APS. Catastrophic APS — a rare, life-threatening form of APS occurring in <1% of patients — is defined as intravascular thrombosis affecting three or more organs, systems and/or tissues either simultaneously or within 1 week with histological confirmation of small vessel occlusion147. Although catastrophic APS usually involves small vessel thrombosis, large vessels are often occluded as well. Of all individuals who develop catastrophic APS, 60% only have APS, whereas 40% have APS associated with another systemic autoimmune disease7. Infections are the most common precipitating factor of catastrophic APS; 49% of individuals who develop catastrophic APS have had a previous infection147. The most common systems involved in catastrophic APS are the kidneys (in 73% of individuals with catastrophic APS), pulmonary system (in 60%), brain (in 56%), cardiac system (in 50%) and skin (in 47%). Among laboratory findings, thrombocytopenia is most frequently observed in individuals with catastrophic APS (in 67%), followed by schistocytes (fragmented red blood cells; in 22%). The 12-year mortality was 37% in the CAPS Registry (an international registry of patients with catastrophic APS)147.



Primary thromboprophylaxis is used to describe the prevention of thrombosis in those without previous clots, whereas secondary thromboprophylaxis describes prevention of clot recurrence following a first thrombotic event. Thromboprophylaxis remains one of the major challenges in APS. Conventional management of cardiovascular risk factors by lifestyle changes is key in primary thromboprophylaxis. The use of antiplatelet agents such as low-dose aspirin (LDA) should be limited to individuals at very high risk3. Secondary thromboprophylaxis is based on anticoagulation, mainly with vitamin K antagonists (such as warfarin or heparin), although direct oral anticoagulants (DOACs; such as rivaroxaban) might have a role as well3.

Primary thromboprophylaxis. The presence of antiphospholipid antibodies in asymptomatic individuals is a risk factor for thrombosis. To date, no randomized controlled trials (RCTs) have eliminated the antiphospholipid antibodies or their activity; thus, lifestyle modifications to address conventional cardiovascular risk factors in individuals with APS, regardless of thrombosis history, concomitant SLE or other features of APS, seem logical despite the lack of clinical trials to support this recommendation148,149. Modifications include cessation of tobacco smoking and addressing hypertension, obesity and hyperlipidaemia.

Management of asymptomatic individuals with persistent antiphospholipid antibodies is assessed on an individual basis, taking the presence of additional cardiovascular risk factors into account3. Individuals with a high-risk profile (that is, those with high antiphospholipid antibody titres, triple positivity or additional cardiovascular risk factors) may be considered for primary prevention with LDA or hydroxychloroquine3. In high-risk situations, such as surgery and long-term immobilization and in postpartum women, all individuals with persistent antiphospholipid antibody positivity should receive thromboprophylaxis with low-molecular-weight heparin (LMWH).

In an RCT of LDA versus placebo150 in those with antiphospholipid antibodies without clinical symptoms, the incidence rate of acute thrombosis in the placebo arm was 0 per 100 patient-years; the trial was underpowered to detect any effect of LDA150. A meta-analysis including 11 (mainly observational) studies of LDA versus placebo involving 1,208 antiphospholipid antibody-positive individuals with 139 thrombotic events suggested that treatment with LDA in those with isolated antiphospholipid antibodies and those with APS is associated with a 50% risk reduction of thrombosis occurrence151. However, LDA treatment is associated with an increased bleeding risk. In a meta-analysis including >95,000 individuals from six RCTs, LDA intake increased the annual risk of developing a major bleed from 0.007% to 0.10%152. Older age (>65 years), male sex, diabetes mellitus and hypertension were risk factors for bleeding in those taking LDA152.

Hydroxychloroquine has been suggested as an alternative to LDA in the setting of primary prevention. Hydroxychloroquine is used in the clinical setting on the basis of empiric evidence and in vitro data153,154, but no rigorous RCTs have been performed155.

Patients with previous obstetrical complications associated with antiphospholipid antibodies have a higher risk of future thrombosis than the general population. No specific treatment recommendation for the prevention of thrombosis in patients with a previous history of antiphospholipid antibody-related pregnancy complications currently exists. However, a retrospective cohort showed that those with obstetrical APS developed a thrombotic event later at a rate of 7.4 per 100 patient-years in the nontreated group and 1.3 per 100 patient-years in the group that received LDA156.

Those with SLE and antiphospholipid antibodies may develop thrombotic events at a rate of 4% per year. The current EULAR guidelines recommend LDA for primary thrombosis prevention for antiphospholipid antibody-positive patients with SLE3,157. Primary thromboprophylaxis with hydroxychloroquine with or without LDA can be considered for individuals with SLE who are positive for lupus anticoagulant or who have persistent anticardiolipin antibodies at medium to high titres157.

Secondary thromboprophylaxis. Venous thromboembolic events can be separated into provoked or unprovoked events; provoking factors include recent hospital admission, the use of oestrogen-containing medication or pregnancy. In provoked events, many physicians give only a short course of anticoagulation (3–6 months), irrespective of the presence of antiphospholipid antibodies, and then provide thromboprophylaxis at the time of haemostatic stress as one would do in anyone with a previous thrombotic event. Unprovoked venous thrombosis and arterial thrombosis are of concern and should be treated with indefinite anticoagulation therapy with a vitamin K antagonist (for example, warfarin) or, occasionally, LMWH3. More recently, the use of DOACs has been considered158. Box 2 outlines the current recommendations of the 13th European Task Force on Antiphospholipid antibodies3 for secondary thromboprophylaxis in APS in the setting of thrombosis3.

Box 2: Secondary thromboprophylaxis in APS

Treatment groups

  • Individuals who are positive for antiphospholipid antibodies and who have had an arterial or venous thrombosis but do not meet criteria for antiphospholipid syndrome (APS)* should be managed in the same way as antiphospholipid antibody-negative patients with thrombotic events.

  • Patients with definite APS* and a first venous thrombosis should receive oral anticoagulant therapy to a target international normalized ratio (INR) of 2–3.

  • Patients with definite APS* and arterial thrombosis should receive vitamin K antagonists with a target INR of >3 or vitamin K antagonists with a target INR of 2–3 in combination with low-dose aspirin.

  • Bleeding risk should always be assessed before starting high-intensity anticoagulant therapy or combined antiplatelet and anticoagulant therapy.

  • For patients without systemic lupus erythematosus with a first noncardioembolic cerebral arterial event who have a low-risk antiphospholipid antibody profile and reversible triggers, antiplatelet agents should be considered on an individual basis.

Duration of treatment

  • Duration of therapy in patients with definite APS* and thrombosis is indefinite3.

  • Anticoagulation could be limited to 3–6 months in patients with a first venous event with a low-risk antiphospholipid antibody profile and a known transient precipitating factor.

Refractory and difficult cases

Potential alternative therapies for patients who have recurrent thrombosis, fluctuating INR levels or major bleeding, or, for those who are at high risk of major bleeding, include long-term low-molecular-weight heparin, hydroxychloroquine or statins.

Treatment recommendations of the 13th European Task Force on Antiphospholipid antibodies3 adapted from the evidence-based recommendations for the prevention and long-term management of thrombosis in individuals who are positive for antiphospholipid antibodies or in those with APS. *Box 1 shows the classification criteria for definite APS2. Low-risk antiphospholipid antibody profile: isolated, intermittently positive anticardiolipin antibodies or anti-β2-glycoprotein 1 antibodies at low titres to medium titres.

Two systematic reviews on vitamin K antagonists have been published123,159. Lim et al.159 included three RCTs involving individuals with APS with a history of arterial and venous thromboembolism. Two of these RCTs focused on the intensity of warfarin used160,161, and both showed comparable rates of thrombosis and bleeding in patients treated with vitamin K antagonists targeted to achieve an international normalized ratio (INR; a parameter used to standardize prothrombin time) of 2–3 compared with high-intensity treatment (that is, a target INR of 3–4). However, the time in range in one of the studies for the INR 3–4 arm was only 14%161, and no benefit of high-intensity treatment was found in the second study160. The systemic review by Lim et al.159 concluded that patients with venous and arterial thrombosis without cerebral events should be treated indefinitely with oral anticoagulants targeted at INR 2–3, whereas a target INR of 1.4–2.8 is recommended for those patients with a previous stroke. However, it is important to note that this systemic review excluded high-risk patients with recurrent vascular events despite anticoagulation, and these patients may require high-intensity treatment with vitamin K antagonists according to current guidelines. By contrast, Ruiz-Irastorza et al.123 conducted a systematic review based on 12 cohort studies and 4 RCTs, including a total of 1,740 patients. Most included studies were of evidence level II or III. In general, recurrent thrombotic events in these studies occurred in patients on vitamin K antagonists with an INR of <3. Patients with previous arterial events were at an increased risk of recurrences when treated with oral anticoagulation to a target INR of 2–3. Notably, recurrences were infrequent among those patients treated with vitamin K antagonists targeting an INR of 3–4 (Ref. 123). In conclusion, the recommendations from this systematic review were to treat patients with a first-time venous thrombosis and definitive APS with warfarin at a target INR of 2–3 and with a target INR >3 in the case of recurrent venous or arterial thrombosis123.

The DOAC rivaroxaban was compared to warfarin (INR target of 2–3) for secondary thromboprophylaxis in APS with previous venous thromboembolism in an open-label, multicentre, noninferiority RCT including 116 patients (the RAPS trial)162. The trial did not reach its primary end point, defined as the change in endogenous thrombin potential at day 42 (that is, it did not reach the noninferiority threshold), but the peak thrombin generation was lower in the rivaroxaban group than in the warfarin groups; thus, rivaroxaban might be an alternative to vitamin K antagonist treatment162. Furthermore, complement activation products of the classical pathway (C3a and C5a) and terminal pathway (SC5b-9) were significantly reduced in patients assigned to rivaroxaban compared with patients assigned to warfarin, highlighting that rivaroxaban may have effects in addition to anticoagulation163. Further studies assessing the role of DOACs in thrombosis associated with APS are currently ongoing and results are eagerly awaited164,​165,​166. Of concern are a handful of case reports with severe adverse events — usually recurrent thrombosis, especially arterial thrombosis — in patients treated with DOACs167,​168,​169.

The Antiphospholipid Antibodies and Stroke Study (APASS), a prospective nested cohort, included 1,770 patients with antiphospholipid antibody-related ischaemic stroke and compared the efficacy of LDA (n = 889) with warfarin (n = 881) on a composite outcome of death, stroke, transient ischaemic attack, myocardial infarction, deep vein thrombosis, pulmonary embolism and other systemic thrombotic events170. No significant difference in event rate between LDA and warfarin was found. However, a major drawback was that patients included in the APASS did not fulfil the APS classification criteria as antiphospholipid antibodies were measured only once (instead of twice with a 12-week period)2. Thus, it is difficult to conclude that the studied cohort consisted of patients with APS170.

The efficacy of hydroxychloroquine in reducing thrombotic rates was first reported in patients with SLE171,172. In patients with thrombotic APS (n = 40), hydroxychloroquine combined with vitamin K antagonists (target INR of 2–3) was not associated with recurrent thromboembolic events, whereas 30% of the control group who were treated with vitamin K antagonists alone experienced a recurrent event (P = 0.0086)173. How hydroxychloroquine exerts its antithrombotic effects in APS remains uncertain. Recent in vivo data suggest that hydroxychloroquine might alter tissue factor expression174. In summary, these studies suggest a role for hydroxychloroquine in the prevention of thrombosis in APS.

Acute management of patients with catastrophic APS is based on anticoagulation, corticosteroids, plasma exchange and/or intravenous immunoglobulin administration according to expert opinion based on data from the CAPS Registry175. No prospective trials have been conducted.

Antiphospholipid antibody-associated clinical manifestations suggesting underlying thrombotic microangiopathic processes (such as skin necrosis or renal disease) require close follow-up176, but no RCTs can inform the most efficacious treatment choices. However, anecdotal evidence supports the use of warfarin with a target INR of 3–4 in those with microvascular thrombosis.

An observational, multicentre study involving 177 patients with thrombotic APS and a median follow-up of 5 years (range 1–26) showed that the thrombotic recurrence rate in APS was 7.5 per 100 patient-years in the first 5 years after the first event despite anticoagulation. Diabetes mellitus, inherited thrombophilia and oral anticoagulation withdrawal were independent risk factors for recurrence177. As such, many clinical APS experts feel that patients with previous arterial thrombosis or recurrent thrombotic events require a more aggressive approach towards secondary prophylaxis than the recommended warfarin treatment targeted at INR 2–3, despite little high-quality evidence1,3. Options are either high-intensity vitamin K antagonist treatment (INR 3–4) or vitamin K antagonists (INR 2–3) combined with other agents such as antiplatelet agents.

Obstetrical complications

With current consensus management (Table 3), the overall live birth rate in women with obstetrical APS is around 70%178. Women with antiphospholipid antibodies and APS should receive counselling before pregnancy and close surveillance during pregnancy131. The specific objective of antenatal care in pregnant women with APS is close observation for maternal thrombosis, antiphospholipid antibody-related renal manifestations and features of pre-eclampsia and monitoring of fetal growth.

Table 3: Management of pregnant women with antiphospholipid antibodies or APS

Risk stratification. A complete history and antiphospholipid antibody profile should be available before conception to aid risk stratification. Risk factors include a high-risk antiphospholipid antibody profile (Box 2), coexisting SLE, previous thrombotic APS and adverse pregnancy outcomes131, of which previous pregnancy outcomes is the best predictor179. Moreover, individuals with obstetrical APS can be separated into three different clinical phenotypes (that is, those with recurrent early pregnancy loss, those with previous ischaemic placental complications and those with previous maternal thromboses); each of these phenotypes is associated with different pregnancy outcomes. In a series of 83 pregnancies in 67 women, women with a previous history of thrombosis had less favourable neonatal outcomes with higher rates of preterm delivery (26.8% versus 4.7%, P = 0.05) and babies of small gestational size (9.5% versus 4.8%, P = 0.003) compared with those with a previous history of recurrent pregnancy loss at <10 weeks of gestation179. Limited data are available assessing pregnancy performance in women with a history of stroke. In one prospectively study including 23 pregnancies in 20 women with APS and previous stroke and/or transient ischaemic attack, 8 women developed pre-eclampsia and 3 women had a recurrent stroke despite treatment with LDA and LMWH180. All women with pulmonary hypertension, including those with APS as a cause, should be discouraged from pregnancy as maternal mortality is as high as 43%1,181.

Obstetrical APS. Despite limited evidence, the standard of care for individuals with obstetrical APS is LDA, intermediate-dose LMWH or unfractionated heparin to prevent antiphospholipid antibody-related obstetrical complications131,182. Mothers with a previous history of thrombosis require intermediate or full-dose anticoagulation (usually LMWH) throughout pregnancy to prevent further thrombotic events. The prevention of early recurrent miscarriages as opposed to placental-mediated complications in the second and third trimesters is the field in obstetrical APS in which most clinical trials have been published. Table 3 summarizes the current recommendations for the treatment of pregnant women with antiphospholipid antibodies or APS.

The current recommendations are based on two RCTs in which women with antiphospholipid antibody-related recurrent first-trimester pregnancy losses were randomly assigned to either LDA or a combination of LDA and unfractionated heparin183,184. The combination of LDA and unfractionated heparin showed a significantly higher rate of live births versus LDA alone (71% versus 42%)183. The other RCT of 50 women alternately assigned either to the combination of LDA and heparin (unfractionated heparin or LMWH) or to LDA alone showed a significantly higher live birth rate associated with LDA and heparin (80% versus 44%)184. However, no differences in outcome with combination therapy versus LDA were found in two other RCTs. Indeed, an RCT of 98 women with recurrent miscarriages found no difference in live birth rate compared with women who were randomized to LDA alone (78% versus 72%)185. In the HepASA trial of 859 women with recurrent pregnancy loss, LDA and LMWH did not result in a significantly better live birth rate than LDA alone (79.1% versus 77.8%)186. The conflicting results of these four trials might be caused by the variation in live birth rates in those women randomized to LDA arms. Two other RCTs on unfractionated heparin compared with LMWH in women with recurrent pregnancy loss and antiphospholipid antibodies did not find a significant difference187,188. A 2015 Cochrane review concluded that treatment with unfractionated heparin in combination with LDA may reduce pregnancy loss by 54%189.

Good clinical evidence is available for the use of LDA in women to reduce the risk of hypertensive disorders in pregnancy (such as pre-eclampsia and eclampsia). As the presence of antiphospholipid antibodies increases the risk of hypertensive disorders in pregnancy, LDA is offered to all individuals who have antiphospholipid antibodies190,​191,​192.

Refractory obstetrical APS. Treatment options to improve pregnancy outcomes refractory to LDA and heparin include low-dose prednisolone in recurrent first-trimester pregnancy loss, which, when combined with conventional treatment with LDA and LMWH administered from positive pregnancy test until week 14, improved the rate of live births in refractory antiphospholipid antibody-related pregnancy loss or losses to 61% in a retrospective cohort of 18 patients193. The use of intravenous immunoglobulins has been assessed in two RCTs. The first trial, in which 40 women with antiphospholipid antibody-related recurrent first-trimester pregnancy loss were randomized to either intravenous immunoglobulins or the combination of LDA and LMWH, failed to show any benefit of intravenous immunoglobulins194. Furthermore, in a second trial, in which 16 women were randomized to intravenous immunoglobulins or the combination of placebo with LDA and LMWH, intravenous immunoglobulins did not show a benefit on obstetrical or neonatal outcomes over LDA and LMWH195. However, women randomly assigned to the intravenous immunoglobulins arm had a lower rate of fetal growth restriction (14% versus 33%, P >0.05) and neonatal intensive care admission (14% versus 44%, P >0.05), which led some clinicians to consider intravenous immunoglobulins as adjuvant in refractory cases196.

A case–control study in patients with established antiphospholipid antibody-related pre-eclampsia and/or intrauterine growth restriction suggests a role for pravastatin (a drug of the statin family)197. Eleven patients treated with pravastatin in combination with LDA and LWMH were compared with women receiving only LDA and LMWH. In all patients in the pravastatin group, signs of pre-eclampsia and placental perfusion remained static, whereas the control group progressed197.

Lastly, some studies suggest that hydroxychloroquine reduces the rate of antiphospholipid antibody-related adverse pregnancy outcomes198,199. In a retrospective, multicentre cohort of women with refractory obstetrical APS, fewer first-trimester miscarriages (81% to 19%, P <0.05) and improved live birth rates to 78% (P <0.05) were reported when women received hydroxychloroquine compared with previous pregnancies in which most received LDA and LMWH199. In another retrospective review of 96 women with persistent antiphospholipid antibodies with 170 pregnancies, hydroxychloroquine use was associated with a higher rate of live births of 67% versus 57% in women treated with LDA and LMWH (P <0.05) and a lower prevalence of pregnancy morbidity in women treated with hydroxychloroquine in addition to standard of care (LDA and LMWH) compared with those who only received standard of care (47% versus 63%; P = 0.004)198. The HYPATIA study, a multicentre RCT of hydroxychloroquine versus placebo in addition to standard of care in women with persistent antiphospholipid antibodies planning for pregnancy, is about to start200.

Late obstetrical complications. There is limited evidence on the prevention of recurrent antiphospholipid antibody-related complications in the second and third trimesters. One RCT involving women with a previous history of antiphospholipid antibody-related delivery at <34 weeks of gestation with hypertensive disorder and/or small-for-gestational-age baby comparing LDA with LMWH plus LDA showed no benefit of LMWH; however, the study was underpowered201. The TIPSS trial, an open-label multicentre trial of 292 women with various thrombophilias, assessed the efficacy of an LMWH, dalteparin, versus no dalteparin in the prevention of a composite outcome of pregnancy-related venous thromboembolism, pregnancy loss and ischaemic placental complications, such as severe pre-eclampsia, intrauterine growth restriction and placental abruption. This study showed that dalteparin did not alter the primary composite outcome but was also underpowered202.

Quality of life

Data from the European multicentre cohort, which included 820 individuals of different ethnicities from 13 European countries who were prospectively followed-up for 10 years, showed that individuals with APS had a mortality of 9.3%, but the severity of APS and the treatment during this period were unclear. Thrombosis and its consequences, such as ischaemic stroke, myocardial infarction, pulmonary embolism and catastrophic APS, were the predominant cause of death, causing one-third of all deaths52.

A history of previous thrombosis has been associated with a reduced quality of life (QOL), irrespective of a diagnosis of APS203, and thrombosis is the best-studied clinical manifestation in terms of QOL in individuals with APS. A case–control study of 826 individuals with SLE with previous thrombosis, of whom 143 had antiphospholipid antibodies, reported a lower score on the mental and physical domains of the 36-Item Short-Form Health Survey204. These findings were similar to an online survey assessing QOL in 270 individuals with APS who were members of the Hughes Foundation, which showed that health-related QOL is significantly lower in individuals with APS than in healthy, age-matched controls205. Another study using this online survey also showed that insufficient social support was linked to a reduced health-related QOL and highlighted the importance of disease-specific patient education206.

Recurrent pregnancy loss, intrauterine growth restriction, pre-eclampsia and/or late fetal loss have an impact on QOL, but to the best of our knowledge no published data have assessed QOL in individuals with obstetrical APS.

Finally, the warfarin treatment itself might have an impact on QOL owing to food interactions and the need for INR monitoring. The RAPS trial collected data on QOL as a secondary outcome, and patients assigned to the rivaroxaban arm reported better QOL than the warfarin group158.


Diagnosis and classification

To increase the future comparability of clinical studies of APS, better standardization of both clinical and laboratory criteria is required. Indeed, the lack of standardization of testing for antiphospholipid antibodies remains a great concern. Furthermore, validation of antibodies directed against prothrombin, the phosphatidylserine–prothrombin complex, specific protein domains such as domain 1 of β2-glycoprotein 1 and proteins that affect the anticoagulant activity of annexin A5 is required, as is validation of the IgA isotype of anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. Additional tests may offer subclassification of APS and better characterization of future risk of thromboses. As we learn more about APS, the clinical criteria included in the diagnostic categories may also change207. Future classification criteria may include several APS-associated manifestations that are not currently included in the criteria2,208,209, including heart valve lesions, renal manifestations, livedo reticularis and thrombocytopenia.

Risk stratification and recurrence risk

Several antiphospholipid antibodies have been identified and weighted with respect to their ability to predict thrombosis and pregnancy loss, resulting in the development of the Global Anti-Phospholipid Syndrome Score (GAPSS)210 (Box 3), which has been validated in APS211 and SLE with antiphospholipid antibodies212. High GAPSS predicted incident thrombosis better than just the presence of the classical antiphospholipid antibodies and, consequently, may guide treatment decisions in clinical practice213. The GAPPS also includes non-APS risk factors, acknowledging the clinically important point that thrombosis risk in individuals with APS is also influenced by concomitant cardiovascular thrombotic risk factors such as arterial hypertension and hyperlipidaemia. It is of interest to stratify for the risk of a first thrombotic event as well as the risk of recurrent thrombosis. The GAPPS is useful in predicting the risk of recurrent thrombosis211,214.

Box 3: The Global Anti-Phospholipid Syndrome Score

The Global Anti-Phospholipid Syndrome Score (GAPSS)210 is a scoring system to predict the risk of thrombosis (either first or recurrent) and pregnancy morbidity. The system consists of a combination of independent risk of thrombosis and pregnancy loss, including the antiphospholipid antibody profile and conventional cardiovascular risk factors. The GAPSS can be calculated for each patient by adding the points corresponding to the different risk factors, including presence of

  • Anticardiolipin antibodies (immunoglobulin G (IgG) or IgM isotype): 5 points

  • Anti-β2-glycoprotein antibodies (IgG or IgM isotype): 4 points

  • Lupus anticoagulant: 4 points

  • Anti-prothrombin/phosphatidylserine complex antibodies (IgG or IgM isotype): 3 points

  • Hyperlipidaemia: 3 points

  • Arterial hypertension: 1 point


As traditional cardiovascular risk factors add to the thrombotic risk associated with the presence of antiphospholipid antibodies, future treatment strategies should ensure modification of concomitant risk factors. The role of statins is of particular interest because they have the dual functionality of inhibiting cholesterol synthesis and modulating inflammatory responses. In the general population, statin treatment also reduces the rates of venous thromboembolism215. Fluvastatin reduces pro-inflammatory and prothrombotic markers in individuals who are positive for antiphospholipid antibodies216 and pravastatin improves pregnancy outcomes in a cohort of pregnant women with refractory APS197.

The positive outcomes associated with statin treatment support the notion that the pathogenesis of APS involves inflammatory and thrombogenic pathways. Thus, cell activation and complement activation mediated by antiphospholipid antibodies play a central part in APS pathology. Accoringly, it is of great interest that in a murine model of obstetrical APS, hydroxychloroquine was able to prevent placental and fetal abnormalities in parallel to lowering serum C5a levels154; we await the results of a trial of hydroxychloroquine in pregnant women with antiphospholipid antibodies (HYPATIA study)200.

Future management trials may include B cell-directed therapy and complement inhibition with rituximab and eculizumab217. In a systematic review of haematopoietic stem cell transplantation in refractory APS, 32 of 44 (73%) individuals were able to discontinue anticoagulation after transplantation218. Although this procedure carries a considerable mortality risk, it is still of interest that remission could be induced in APS. As our knowledge of the pathogenesis of APS steadily increases, we will gain a better understanding of APS and will be able to identify opportunities to investigate new paradigm-shifting therapeutic targets.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

How to cite this article

Schreiber, K. et al. Antiphospholipid syndrome. Nat. Rev. Dis. Primers 4, 17103 (2018).


  1. 1.

    , , & Antiphospholipid syndrome. Lancet 376, 1498–1509 (2010).

  2. 2.

    et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295–306 (2006). This paper outlines the current APS classification criteria, commonly referred to as ‘Miyakis criteria’.

  3. 3.

    et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 20, 206–218 (2011).

  4. 4.

    & Infodemiology of systemic lupus erythematous using Google Trends. Lupus 26, 886–889 (2017).

  5. 5.

    et al. Variability of cut-off values for the detection of lupus anticoagulants: results of an international multicenter multiplatform study. J. Thromb. Haemost. 15, 1180–1190 (2017).

  6. 6.

    & Epidemiology of the Antiphospholipid Syndrome (Elsevier, 2016).

  7. 7.

    et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun. Rev. 15, 1120–1124 (2016).

  8. 8.

    & in Handbook of Systemic Autoimmune Diseases Vol. 10 (eds Cervera, R., Reverter, J. C. & Khamashta, M.) 13–34 (Elsevier, 2009).

  9. 9.

    et al. Anti-beta 2 glycoprotein I antibodies in centenarians. Exp. Gerontol. 39, 1459–1465 (2004).

  10. 10.

    et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res. 65, 1869–1873 (2013).

  11. 11.

    et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 8, 998–1005 (2009).

  12. 12.

    et al. Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. Ann. Rheum. Dis. 71, 61–66 (2012).

  13. 13.

    et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 119, 2624–2632 (2012).

  14. 14.

    , , , & Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum. Reprod. 20, 1729–1732 (2005).

  15. 15.

    et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun. Rev. 14, 387–395 (2015).

  16. 16.

    , , & The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb. Res. 128, 77–85 (2011).

  17. 17.

    et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am. J. Obstetr. Gynecol. 169, 1411–1417 (1993).

  18. 18.

    et al. Diagnostic tests for evaluation of stillbirth: stillbirth collaborative research network. Obstet. Gynecol. 129, 699–706 (2017).

  19. 19.

    , , & Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 61, 29–36 (2009).

  20. 20.

    & The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun. Rev. 9, A299–A304 (2010).

  21. 21.

    , , & Anti-cardiolipin and anti-beta 2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizures. Lupus 10, 45–50 (2001).

  22. 22.

    et al. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J. Rheumatol. 32, 622–628 (2005).

  23. 23.

    , , & Infections and vaccines in the etiology of antiphospholipid syndrome. Curr. Opin. Rheumatol. 24, 389–393 (2012).

  24. 24.

    et al. Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 63, 3960–3968 (2011).

  25. 25.

    et al. Induction of anti-β2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J. Thromb. Haemost. 9, 2447–2456 (2011).

  26. 26.

    et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118, 4714–4718 (2011).

  27. 27.

    , , & Familial association of the lupus anticoagulant. Br. J. Haematol. 45, 89–96 (1980).

  28. 28.

    , , & Familial occurrence of the antiphospholipid syndrome. J. Clin. Pathol. 42, 495–497 (1989).

  29. 29.

    , , & Different clinical presentations of a lupus anticoagulant in the same family. Klin. Wochenschr. 69, 340–344 (1991).

  30. 30.

    , , & Genetic aspects of the antiphospholipid syndrome: an update. Autoimmun. Rev. 15, 433–439 (2016).

  31. 31.

    et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 74, 1011–1018 (2015).

  32. 32.

    , , , & Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin. Thromb. Hemost. 37, 885–896 (2011).

  33. 33.

    , & Pathophysiology of thrombotic APS: where do we stand? Lupus 21, 704–707 (2012).

  34. 34.

    et al. Thrombogenicity of β2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 101, 157–162 (2003).

  35. 35.

    et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 117, 1408–1414 (2011).

  36. 36.

    et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 106, 2340–2346 (2005).

  37. 37.

    et al. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology 54, 722–727 (2015).

  38. 38.

    et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2-glycoprotein I: proof of concept. J. Thromb. Haemost. 7, 833–842 (2009).

  39. 39.

    , , & Evolutionary conservation of the lipopolysaccharide binding site of β2-glycoprotein I. Thromb. Haemost. 106, 1069–1075 (2011).

  40. 40.

    , , , & A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br. J. Haematol. 135, 214–219 (2006).

  41. 41.

    et al. Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model. Lupus 12, 364–369 (2003).

  42. 42.

    et al. Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice. J. Thromb. Haemost. 14, 1011–1020 (2016).

  43. 43.

    , , , & Anti-β2glycoprotein I antibodies from leprosy patients do not show thrombogenic effects in an in vivo animal model. J. Thromb. Haemost. 9, 859–861 (2011).

  44. 44.

    & The significance of autoantibodies against β2-glycoprotein I. Blood 120, 266–274 (2012). This paper highlights the importance of anti-β2-glycoprotein 1 in APS.

  45. 45.

    , & Extracellular vesicles in the antiphospholipid syndrome. Semin. Thromb. Hemost. (2017).

  46. 46.

    et al. Dimers of β2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2’. J. Biol. Chem. 278, 33831–33838 (2003).

  47. 47.

    & Cellular signaling by antiphospholipid antibodies. J. Thromb. Haemost. 12, 773–775 (2014).

  48. 48.

    , , & Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann. NY Acad. Sci. 1051, 413–420 (2005).

  49. 49.

    , , , & Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system. Curr. Rheumatol Rep. 11, 77–81 (2009).

  50. 50.

    Progress in the understanding of the protein C anticoagulant pathway. Int. J. Hematol. 79, 109–116 (2004).

  51. 51.

    & Acquired inhibitors of blood coagulation. Prog. Hemost. Thromb. 1, 75–95 (1972).

  52. 52.

    et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann. Rheum. Dis. 74, 1011–1018 (2015).

  53. 53.

    & The obstetric antiphospholipid syndrome. J. Reproductive Immunol. 77, 41–50 (2008).

  54. 54.

    , , & Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 352, 1037–1038 (1998).

  55. 55.

    et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum. 43, 140–150 (2000).

  56. 56.

    , , & Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 30, 473–482 (2009).

  57. 57.

    , & Synthesis of β2 glycoprotein 1 by the human placenta. Placenta 18, 403–410 (1997).

  58. 58.

    et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am. J. Reprod. Immunol. 62, 96–111 (2009).

  59. 59.

    et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity. Am. J. Reprod. Immunol. 63, 339–348 (2010).

  60. 60.

    et al. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am. J. Reprod. Immunol. 66, 286–296 (2011).

  61. 61.

    , , , & Aspirin-triggered lipoxin prevents antiphospholipid antibody effects on human trophoblast migration and endothelial cell interactions. Arthritis Rheumatol. 67, 488–497 (2015).

  62. 62.

    et al. ApoE receptor 2 mediation of trophoblast dysfunction and pregnancy complications induced by antiphospholipid antibodies in mice. Arthritis Rheumatol. 68, 730–739 (2016).

  63. 63.

    et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 195, 211–220 (2002).

  64. 64.

    et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112, 1644–1654 (2003).

  65. 65.

    , & TNF-α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J. Immunol. 174, 485–490 (2005).

  66. 66.

    , , , & Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203, 2165–2175 (2006).

  67. 67.

    et al. Prevention of defective placentation and pregnancy loss by blocking innate immune pathways in a syngeneic model of placental insufficiency. J. Immunol. 195, 1129–1138 (2015).

  68. 68.

    , & Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10, 1222–1226 (2004). This study supports the role of the complement system in antiphospholipid antibody-related pregnancy morbidity in a murine model.

  69. 69.

    , , & Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am. J. Obstet. Gynecol. 196, 167.e1–167.e5 (2007).

  70. 70.

    et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J. Pathol. 225, 502–511 (2011).

  71. 71.

    & Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun. Rev. 14, 446–471 (2015).

  72. 72.

    et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 8, e1001013 (2011).

  73. 73.

    et al. Complement activation in patients with primary antiphospholipid syndrome. Ann. Rheum. Dis. 68, 1030–1035 (2009).

  74. 74.

    et al. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb. Haemost. 107, 423–429 (2012).

  75. 75.

    et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 177, 4794–4802 (2006).

  76. 76.

    , , , & Tumor necrosis factor-α is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am. J. Obstetr. Gynecol. 170, 1752–1759 (1994).

  77. 77.

    et al. Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal pregnancies and in pregnancies complicated by preeclampsia. J. Matern. Fetal Neonatal Med. 23, 880–886 (2010).

  78. 78.

    et al. Immunolocalization of tumour necrosis factor-α (TNF-α) in the placental bed of normotensive and hypertensive human pregnancies. Placenta 19, 231–239 (1998).

  79. 79.

    et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 67, 2990–3003 (2015).

  80. 80.

    et al. Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies. Lupus Sci. Med. 3, e000134 (2016).

  81. 81.

    , , & How we diagnose the antiphospholipid syndrome. Blood 113, 985–994 (2009).

  82. 82.

    et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 7, 1737–1740 (2009). This publication outlines the current SSC-ISTH guidelines for the detection of antiphospholipid antibodies.

  83. 83.

    et al. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J. Thromb. Haemost. 12, 792–795 (2014).

  84. 84.

    Standardization of antiphospholipid antibody assays. Where do we stand? Lupus 21, 718–721 (2012).

  85. 85.

    No more mixing tests required for integrated assay systems in the laboratory diagnosis of lupus anticoagulants? J. Thromb. Haemost. 8, 1120–1122 (2010).

  86. 86.

    & Mixing studies in lupus anticoagulant testing are required at least in some type of samples. J. Thromb. Haemost. 13, 1475–1478 (2015).

  87. 87.

    & More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J. Thromb. Haemost. 9, 2126–2127 (2011).

  88. 88.

    Antiphospholipid antibody testing and standardization. Int. J. Lab. Hematol. 36, 352–363 (2014).

  89. 89.

    , , & Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun. Rev. 16, 173–178 (2017).

  90. 90.

    Combining Taipan snake venom time/Ecarin time screening with the mixing studies of conventional assays increases detection rates of lupus anticoagulants in orally anticoagulated patients. Thromb. J. 5, 12 (2007).

  91. 91.

    Antiphospholipid antibody testing and standardization. Int. J. Lab. Hematol. 36, 352–363 (2014).

  92. 92.

    et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335, 1544–1547 (1990).

  93. 93.

    , , & Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int. J. Lab. Hematol. 34, 630–640 (2012).

  94. 94.

    , , & Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J. Thromb. Haemost. 8, 1540–1546 (2010).

  95. 95.

    , , & IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J. Thromb. Haemost. 14, 1530–1548 (2016).

  96. 96.

    et al. Measuring IgA anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS ONE 11, e0156407 (2016).

  97. 97.

    et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun. Rev. 13, 917–930 (2014).

  98. 98.

    , , , & Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I-Anticardiolipin and anti-beta2-glycoprotein I antibodies. Semin. Thromb. Hemost 38, 390–403 (2012).

  99. 99.

    et al. Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs. PLoS ONE 8, e71402 (2013).

  100. 100.

    et al. A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system. J. Thromb. Haemost. 15, 91–95 (2017).

  101. 101.

    Antiphospholipid antibodies: evaluation of the thrombotic risk. Thromb. Res. 130 (Suppl. 1), S37–S40 (2012).

  102. 102.

    , & Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood 115, 870–878 (2010).

  103. 103.

    , & Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients. Thromb. Haemost. 105, 736–738 (2011).

  104. 104.

    et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb. Haemost. 93, 1147–1152 (2005).

  105. 105.

    et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 8, 237–242 (2010).

  106. 106.

    Four good reasons to appreciate triple positivity. Pol. Arch. Med. Wewn 126, 7–8 (2016).

  107. 107.

    , , & Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus 23, 1468–1476 (2014).

  108. 108.

    et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J. Thromb. Haemost. 11, 1527–1531 (2013).

  109. 109.

    et al. APS — diagnostics and challenges for the future. Autoimmun. Rev. 15, 1031–1033 (2016).

  110. 110.

    & Challenges in the diagnosis of the antiphospholipid syndrome. Clin. Chem. 56, 930–940 (2010).

  111. 111.

    , , , & Examining the prevalence of non-criteria anti phospholipid antibodies in patients with anti phospholipid syndrome: a systematic review. Rheumatology 54, 2042–2050 (2015).

  112. 112.

    , , & IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105, 1540–1545 (2005).

  113. 113.

    et al. The association between circulating antibodies against domain I of β2-glycoprotein I and thrombosis: an international multicenter study. J. Thromb. Haemost. 7, 1767–1773 (2009).

  114. 114.

    et al. Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus 25, 911–916 (2016).

  115. 115.

    , & Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J. Thromb. Haemost. 14, 1779–1787 (2016).

  116. 116.

    et al. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J. Thromb. Haemost. 13, 782–787 (2015).

  117. 117.

    et al. Detection of IgG anti-domain I β2 glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin. Chim. Acta 446, 201–205 (2015).

  118. 118.

    et al. Role of antiphospholipid score and anti-β2-glycoprotein I domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin. Chim. Acta 431, 174–178 (2014).

  119. 119.

    et al. Evaluation of the diagnostic potential of antibodies to β2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. Sci. Rep. 6, 23839 (2016).

  120. 120.

    , , , & Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome. Thromb. Res. 153, 90–94 (2017).

  121. 121.

    et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb. Haemost. 111, 354–364 (2014).

  122. 122.

    et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 46, 1019–1027 (2002).

  123. 123.

    , & A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 57, 1487–1495 (2007).

  124. 124.

    , , & Antiphospholipid syndrome. Best Pract. Res. Clin. Rheumatol. 30, 133–148 (2016).

  125. 125.

    et al. European registry of babies born to mothers with antiphospholipid syndrome. Ann. Rheum. Dis. 72, 217–222 (2013).

  126. 126.

    et al. Multicenter evaluation of obstetric and maternal outcome in prospectively followed pregnant patients with confirmed positivity for antiphospholipid antibodies (aPL) [abstract]. Arthritis Rheumatol. 67 (suppl 10), 2530 (2015).

  127. 127.

    et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci. Med. 3, e000131 (2016).

  128. 128.

    , & Pregnancy, vascular tone, and maternal hemodynamics: a crucial adaptation. Obstet. Gynecol. Surv. 55, 574–581 (2000).

  129. 129.

    et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology 45, 332–338 (2006).

  130. 130.

    , , & Primary antiphospholipid syndrome in pregnancy: An analysis of outcome in a cohort of 33 women treated with a rigorous protocol. Editorial comment. Obstet. Gynecol. Surv. 60, 501–503 (2005).

  131. 131.

    et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 76, 476–485 (2017).

  132. 132.

    , & Neurological manifestations of antiphospholipid syndrome. Eur. J. Clin. Invest. 40, 350–359 (2010).

  133. 133.

    et al. Features associated with epilepsy in the antiphospholipid syndrome. J. Rheumatol 31, 1344–1348 (2004).

  134. 134.

    , , & Cardiac manifestations in antiphospholipid syndrome. Autoimmun. Rev. 6, 379–386 (2007).

  135. 135.

    et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5, 196–205 (1996).

  136. 136.

    et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 20, 165–173 (2011).

  137. 137.

    , , & Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin. Arthritis Rheum. 27, 27–35 (1997).

  138. 138.

    et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112, 3337–3347 (2005).

  139. 139.

    et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology 210, 749–754 (2005).

  140. 140.

    et al. Autoimmune hemolytic anaemia in the antiphospholipid syndrome. Lupus 15, 473–477 (2006).

  141. 141.

    et al. Pulmonary events in antiphospholipid syndrome: influence of antiphospholipid antibody type and levels. Scand. J. Rheumatol 41, 223–226 (2012).

  142. 142.

    et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 52, 1785–1793 (2005).

  143. 143.

    et al. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Med. (Baltimore) 78, 209–219 (1999).

  144. 144.

    & Livedo reticularis as a criterion for antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 32, 138–144 (2007).

  145. 145.

    Identification and treatment of APS renal involvement. Lupus 23, 1276–1278 (2014).

  146. 146.

    , , & Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy. Pediatr. Nephrol. 26, 979–985 (2011).

  147. 147.

    et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12, 530–534 (2003).

  148. 148.

    , , , & Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM 93, 523–530 (2000).

  149. 149.

    , , & Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J. Rheumatol. 36, 1195–1199 (2009).

  150. 150.

    et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 56, 2382–2391 (2007).

  151. 151.

    et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun. Rev. 13, 281–291 (2014).

  152. 152.

    et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849–1860 (2009).

  153. 153.

    , , & New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 8, 522–533 (2012).

  154. 154.

    et al. Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. J. Autoimmun. 75, 30–38 (2016).

  155. 155.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  156. 156.

    et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 44, 1466–1467 (2001).

  157. 157.

    et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann. Rheum. Dis. 67, 195–205 (2008).

  158. 158.

    , , & Direct oral anticoagulants for thromboprophylaxis in patients with antiphospholipid syndrome. Semin. Thromb. Hemost. (2017).

  159. 159.

    , & Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295, 1050–1057 (2006).

  160. 160.

    et al. A randomized clinical trial of high-intensity warfarin versus conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 3, 848–853 (2005).

  161. 161.

    et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 349, 1133–1138 (2003).

  162. 162.

    et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 3, e426–436 (2016). This is the first RCT of DOACs versus warfarin in APS.

  163. 163.

    et al. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J. Thromb. Haemost. 14, 2177–2186 (2016).

  164. 164.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  165. 165.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  166. 166.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  167. 167.

    , & Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban. Thromb. Res. 153, 37–39 (2017).

  168. 168.

    et al. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb. Haemost. 112, 947–950 (2014).

  169. 169.

    & New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am. J. Hematol. 89, 1017 (2014).

  170. 170.

    et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291, 576–584 (2004).

  171. 171.

    et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11, 356–361 (2002).

  172. 172.

    et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577–583 (2006). This study emphasizes the antithrombotic effect of antimalarials in individuals with SLE.

  173. 173.

    et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J. Thromb. Haemost. 11, 1927–1929 (2013).

  174. 174.

    et al. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (2017). This paper suggests that hydroxychloroquine reduces soluble tissue factor in patients with APS.

  175. 175.

    & Catastrophic antiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’. Lupus 19, 412–418 (2010).

  176. 176.

    et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus 20, 174–181 (2011).

  177. 177.

    et al. Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study). Lupus 25, 479–485 (2016).

  178. 178.

    , , & Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 49, 281–288 (2010).

  179. 179.

    et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 19, 58–64 (2010).

  180. 180.

    , & Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus 21, 1183–1189 (2012).

  181. 181.

    et al. Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology. Eur. J. Heart Fail. 18, 1119–1128 (2016).

  182. 182.

    et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 123, 404–413 (2014).

  183. 183.

    , , & Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314, 253–257 (1997).

  184. 184.

    Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am. J. Obstet. Gynecol. 174, 1584–1589 (1996).

  185. 185.

    , & Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet. Gynecol. 100, 408–413 (2002).

  186. 186.

    et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J. Rheumatol. 36, 279–287 (2009).

  187. 187.

    , , & Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil. Steril. 83, 684–690 (2005).

  188. 188.

    et al. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int. J. Gynaecol. Obstet. 112, 211–215 (2011).

  189. 189.

    , , & Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2, CD002859 (2005).

  190. 190.

    National Collaborating Centre for Women's and Children's Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy (RCOG Press, 2010).

  191. 191.

    et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 160, 695–703 (2014).

  192. 192.

    , & Intrauterine growth restriction: screening, diagnosis, and management. J. Obstet. Gynaecol. Can. 35, 741–748 (2013).

  193. 193.

    , , , & First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 117, 6948–6951 (2011).

  194. 194.

    et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum. 48, 728–731 (2003).

  195. 195.

    et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am. J. Obstet. Gynecol. 182, 122–127 (2000).

  196. 196.

    , , & Intravenous immunoglobulin in pregnancy: a chance for patients with an autoimmune disease. Isr. Med. Assoc. J. 9, 553–554 (2007).

  197. 197.

    et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J. Clin. Invest. 126, 2933–2940 (2016). This case-control study highlights the potential role of pravastatin in refractory obstetrical APS.

  198. 198.

    et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am. J. Obstet. Gynecol. 214, 273.e1–273.e8 (2016). This paper highlights the possible role of hydroxychloroquine in improving antiphospholipid antibody-related pregnancy outcomes.

  199. 199.

    et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun. Rev. 14, 498–502 (2015).

  200. 200.

    et al. HYdroxychloroquine to improve pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin. Thromb. Hemost. 43, 562–571 (2017).

  201. 201.

    et al. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur. J. Obstet. Gynecol. Reprod. Biol. 197, 168–173 (2016).

  202. 202.

    et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet 384, 1673–1683 (2014).

  203. 203.

    et al. The impact of venous thrombosis on quality of life. Thromb. Res. 114, 11–18 (2004).

  204. 204.

    et al. Thrombovascular events affect quality of life in patients with systemic lupus erythematosus. J. Rheumatol 38, 1017–1019 (2011).

  205. 205.

    , , , & Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36. Lupus 24, 174–179 (2015).

  206. 206.

    , , , & The relationship between social support and health-related quality of life in patients with antiphospholipid (hughes) syndrome. Mod. Rheumatol. (2017).

  207. 207.

    , , , & Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin. Arthritis Rheum. 21, 275–286 (1992).

  208. 208.

    & Non-criteria manifestations of antiphospholipid syndrome. Lupus 19, 424–427 (2010).

  209. 209.

    et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun. Rev. 14, 401–414 (2015).

  210. 210.

    , , & Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann. Rheum. Dis. 72, 142–143 (2013). This paper outlines the development of the GAPSS.

  211. 211.

    et al. The global anti-phospholipid syndrome score in primary APS. Rheumatology 54, 134–138 (2015).

  212. 212.

    et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res. 66, 1915–1920 (2014).

  213. 213.

    et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology 54, 2071–2075 (2015).

  214. 214.

    et al. An independent validation of the Global Anti-Phospholipid Syndrome Score in a Japanese cohort of patients with autoimmune diseases. Lupus 24, 774–775 (2015).

  215. 215.

    et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360, 1851–1861 (2009).

  216. 216.

    et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann. Rheum. Dis. 73, 1176–1180 (2014).

  217. 217.

    & Catastrophic antiphospholipid syndrome: candidate therapies for a potentially lethal disease. Annu. Rev. Med. 68, 287–296 (2017).

  218. 218.

    et al. Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun. Rev. 16, 469–477 (2017).

  219. 219.

    , & Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation. Arthritis Rheumatol. 69, 1710–1721 (2017).

  220. 220.

    Epidemiology of the antiphospholipid antibody syndrome. J. Autoimmun. 15, 145–151 (2000).

  221. 221.

    , & Prevalence of antiphospholipid antibodies in Syrian patients with thrombosis. Iran. J. Immunol. 6, 154–159 (2009).

  222. 222.

    , , & Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102, 2717–2723 (2003).

  223. 223.

    et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med. 117, 997–1002 (1992).

  224. 224.

    et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J. Thromb. Haemost. 3, 1993–1997 (2005).

  225. 225.

    et al. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J. Thromb. Haemost. 5, 2421–2428 (2007).

  226. 226.

    [No authors listed.] Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS). Neurology 48, 91–94 (1997).

  227. 227.

    et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann. Rheum. Dis. 74, 2028–2033 (2015).

  228. 228.

    , , , & Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J. Rheumatol 33, 2214–2221 (2006).

  229. 229.

    , , & Beta2-glycoprotein I dependent anticardiolipin antibodies and lupus anticoagulant in patients with recurrent pregnancy loss. J. Postgrad. Med. 48, 5–10 (2002).

  230. 230.

    et al. Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss. Eur. J. Obstet. Gynecol. Reprod. Biol. 119, 164–170 (2005).

  231. 231.

    et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N. Engl. J. Med. 377, 613–622 (2017).

  232. 232.

    et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J. Thromb. Haemost. 7, 58–64 (2009).

  233. 233.

    et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding — part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 55, 1693–1697 (2016).

  234. 234.

    et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding — part II: analgesics and other drugs used in rheumatology practice. Rheumatology 55, 1698–1702 (2016).

  235. 235.

    Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a (Royal College of Obstetricians and Gynaecologists, 2015).

Download references


The authors thank the Guy's and St Thomas’ Charity for their support of K.S.

Author information


  1. Thrombosis & Thrombophilia, Guy's and St Thomas’ Hospital NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, UK.

    • Karen Schreiber
    •  & Beverley J. Hunt
  2. Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

    • Karen Schreiber
    •  & Soren Jacobsen
  3. Center of Research of Immunopathology and Rare Diseases and SCDU Nephrology and Dialysis, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

    • Savino Sciascia
  4. Synapse Research Institute, Maastricht, The Netherlands.

    • Philip G. de Groot
  5. Coagulation Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium.

    • Katrien Devreese
  6. Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain.

    • Guillermo Ruiz-Irastorza
  7. Department of Medicine, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York, USA.

    • Jane E. Salmon
  8. Zabuldowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.

    • Yehuda Shoenfeld
    •  & Ora Shovman
  9. Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

    • Yehuda Shoenfeld
  10. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

    • Ora Shovman


  1. Search for Karen Schreiber in:

  2. Search for Savino Sciascia in:

  3. Search for Philip G. de Groot in:

  4. Search for Katrien Devreese in:

  5. Search for Soren Jacobsen in:

  6. Search for Guillermo Ruiz-Irastorza in:

  7. Search for Jane E. Salmon in:

  8. Search for Yehuda Shoenfeld in:

  9. Search for Ora Shovman in:

  10. Search for Beverley J. Hunt in:


Introduction (G.R.-I.); Epidemiology (S.S.); Mechanisms/pathophysiology (J.E.S. and P.G.d.G.); Diagnosis, screening and prevention (K.D., Y.S. and O.S.); Management (K.S. and B.J.H.); Quality of life (K.S. and S.S.); Outlook (S.J.); Overview of Primer (K.S. and B.J.H.).

Competing interests

J.E.S. has received an investigator-initiated grant from UCB. The other authors declare no competing interests.

Corresponding author

Correspondence to Beverley J. Hunt.

About this article

Publication history




Further reading